Compare Tripadvisor Inc Common Stock (TRIP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tripadvisor Inc Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Tripadvisor Inc Common Stock trades at $10.48 (market cap $1.28B), while State Street SPDR S&P Biotech ETF trades at $159.45. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| TRIP | XBI | |
|---|---|---|
Market Cap | $1.28B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $19.14 | $164.28 |
52-Week Low | $9.24 | $86.92 |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tripadvisor (TRIP) trades at $10.78, flat on the day, with a bearish technical signal but bullish oscillators. The company reported Q2 2026 EPS of $0.35, missing estimates, though revenue reached $1.89B in 2025 with a net income margin of 2.11%. Recent news highlights competitive pressures from AI travel tools and the pending $700M sale of TheFork to American Express, providing a cash infusion.
Outlook remains mixed; the stock is undervalued on P/S (0.72) but carries a high P/E (127.18). Risks include stiff competition and earnings misses, yet analyst consensus targets $13.29, suggesting 23% upside. Investor sentiment is cautious, with 62.5% hold ratings, but Viator's U.S. leadership offers a growth avenue amid challenges.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
